

Application No. 10/607,752  
Attorney Docket: 11000.1042c3  
Response to Office Action mailed November 4, 2005

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-5 (cancelled).

Claim 6 (withdrawn): A genetic construct comprising at least one polynucleotide according to any one of claims 3-5.

Claim 7 (withdrawn): The genetic construct of claim 6, wherein the construct comprises a sequence selected from the group consisting of SEQ ID NO: 56-58 and 82-89.

Claim 8 (withdrawn): A host cell transformed with a genetic construct according to any one of claims 6 and 7.

Claims 9 and 10 (cancelled).

Claim 11 (withdrawn): A polynucleotide encoding a fusion protein of claim 9, wherein the polynucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 56-58, 82-89 and 115.

Claim 12 (cancelled).

Claim 13 (withdrawn): A composition comprising at least one polynucleotide according to any one of claims 3-5 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

Claim 14 (previously presented): A composition comprising at least one fusion protein according to claim 24 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

Application No. 10/607,752  
Attorney Docket: 11000.1042c3  
Response to Office Action mailed November 4, 2005

Claim 15 (original): The composition of claim 14, wherein the composition further comprises a flt3 ligand.

Claim 16 (withdrawn): A composition comprising at least one genetic construct according to claim 6, and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

Claim 17 (currently amended): A method for enhancing an immune response in a patient, comprising administering to the patient a composition according to any one of claims ~~14, 15, 26 and 27~~ 14 and 15.

Claim 18 (original): The method of claim 17, wherein the immune response is a Th1 response.

Claim 19 (original): The method of claim 17, wherein the composition activates at least one cell selected from the group consisting of T cells and NK cells.

Claim 20 (original): The method of claim 17, wherein the composition stimulates cytokine production.

Claim 21 (original): The method of claim 17, wherein the composition induces long-term memory cells.

Claim 22 (currently amended): A method for the treatment of a disorder selected from the group consisting of immune disorders, and infectious diseases ~~and cancer~~ in a patient, comprising administering to the patient a composition according to any one of claims ~~14, 15, 26 and 27~~ 14 and 15.

Application No. 10/607,752  
Attorney Docket: 11000.1042c3  
Response to Office Action mailed November 4, 2005

Claim 23 (currently amended): A method for the treatment of a disorder in a patient, comprising administering to the patient a composition according to any one of claims ~~14, 15, 26 and 27~~ 14 and 15, wherein the disorder is tuberculosis.

Claim 24 (previously presented): A fusion protein comprising SEQ ID NO: 116.

Claim 25 (previously presented): A fusion protein comprising a sequence having at least 95% identity to SEQ ID NO: 116, wherein the fusion protein possesses at least one property selected from the group consisting of:

(a) an ability to stimulate proliferation of T cells from individuals exposed to *Mycobacterium tuberculosis*; and

(b) an ability to stimulate interferon-gamma secretion from T cells from individuals exposed to *Mycobacterium tuberculosis*.

Claim 26 (previously presented): A composition comprising at least one fusion protein according to claim 25 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

Claim 27 (previously presented): The composition of claim 26, wherein the composition further comprises a flt3 ligand.

Claim 28 (currently amended): [A] The fusion protein encoded by the polynucleotide sequence of SEQ ID NO: 115.

Claim 29 (new): A method for enhancing an immune response in a patient, comprising administering to the patient a composition according to any one of claims 26 and 27.

Claim 30 (new): A method for the treatment of a disorder selected from the group consisting of immune disorders and infectious diseases in a patient, comprising administering to the patient a composition according to any one of claims 26 and 27.

Application No. 10/607,752  
Attorney Docket: 11000.1042c3  
Response to Office Action mailed November 4, 2005

Claim 31 (new): A method for the treatment of a disorder in a patient, comprising administering to the patient a composition according to any one of claims 26 and 27, wherein the disorder is tuberculosis.